Author

C. C. Pastrana

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Sensitivity to ATR-CHK1 pathway inhibition in MDS/AML is enhanced by SRSF2 mutations and reduced by RUNX1 loss.

SRSF2 mutations occur in 5-15% of acute myeloid leukemia (AML) and ~15% of myelodysplastic neoplasms (MDS), are enriched in elderly/secondary AML, and lack mutation-directed therapy. We aimed to identify vulnerabilities in MDS/AML with SRSF2 mutations. Ex vivo drug-sensitivity testing of bone marrow cells from AML pati...

S. Eldfors, Sumit Rai, Vineet Sharma et al. · Leukemia · 0 citations

Review Open access Jul 2026

Targeting Bruton’s Tyrosine Kinase in CLL: Selectivity, Resistance Mechanisms, and Emerging Therapeutic Strategies

A summary of the design of irreversible inhibitors, reversible inhibitors, and Proteolysis-targeting chimera (PROTAC) degraders targeting BTK is provided and how the design of these inhibitors and PROTACs leads to a more selective inhibition and degradation of BTK is reviewed.

Eduardo Bravo, C. C. Pastrana, Erica N Lamkin et al. · Cells · 0 citations

Jul 2026

Abstract B085: Selective oral STK17A inhibitor UMF814A targets a previously unrecognized dark kinase vulnerability in spliceosome-mutant MDS and AML

Myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML) remain therapeutically challenging, particularly in patients with spliceosome-mutant disease, where effective targeted options are lacking. Mutations in SF3B1, SRSF2, and U2AF1 define a biologically distinct subset associated with aberrant RNA splic...

E. Spinetti, C. C. Pastrana, E. Bravo et al. · Clinical Cancer Research · 0 citations